In Phase A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be provided as "increase-on" therapy. In https://johnathanwitfp.activablog.com/31341687/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed